WO2011108711A1 - 妊娠高血圧症候群モデル動物とその治療方法 - Google Patents
妊娠高血圧症候群モデル動物とその治療方法 Download PDFInfo
- Publication number
- WO2011108711A1 WO2011108711A1 PCT/JP2011/055087 JP2011055087W WO2011108711A1 WO 2011108711 A1 WO2011108711 A1 WO 2011108711A1 JP 2011055087 W JP2011055087 W JP 2011055087W WO 2011108711 A1 WO2011108711 A1 WO 2011108711A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sflt1
- pregnancy
- plgf
- hypertension syndrome
- placenta
- Prior art date
Links
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 57
- 206010070538 Gestational hypertension Diseases 0.000 title claims abstract description 54
- 201000005624 HELLP Syndrome Diseases 0.000 title claims abstract description 34
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 title claims abstract description 34
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 title claims abstract description 34
- 241001465754 Metazoa Species 0.000 title abstract description 62
- 210000002826 placenta Anatomy 0.000 claims abstract description 68
- 241000282414 Homo sapiens Species 0.000 claims abstract description 66
- 230000003169 placental effect Effects 0.000 claims abstract description 61
- 201000001474 proteinuria Diseases 0.000 claims abstract description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 47
- 206010020772 Hypertension Diseases 0.000 claims abstract description 46
- 206010061989 glomerulosclerosis Diseases 0.000 claims abstract description 45
- 230000004064 dysfunction Effects 0.000 claims abstract description 44
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims abstract description 42
- 208000030941 fetal growth restriction Diseases 0.000 claims abstract description 42
- 206010070531 Foetal growth restriction Diseases 0.000 claims abstract description 40
- 230000035935 pregnancy Effects 0.000 claims abstract description 35
- 208000024891 symptom Diseases 0.000 claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 238000012216 screening Methods 0.000 claims abstract description 12
- 108010082093 Placenta Growth Factor Proteins 0.000 claims abstract 4
- 102100035194 Placenta growth factor Human genes 0.000 claims description 83
- 102000039446 nucleic acids Human genes 0.000 claims description 76
- 108020004707 nucleic acids Proteins 0.000 claims description 76
- 150000007523 nucleic acids Chemical class 0.000 claims description 76
- 210000002459 blastocyst Anatomy 0.000 claims description 50
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 41
- 239000000126 substance Substances 0.000 claims description 34
- 201000011461 pre-eclampsia Diseases 0.000 claims description 30
- 210000004340 zona pellucida Anatomy 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000006698 induction Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 abstract description 63
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract description 42
- 229960002965 pravastatin Drugs 0.000 abstract description 42
- 239000003814 drug Substances 0.000 abstract description 27
- 229940124597 therapeutic agent Drugs 0.000 abstract description 17
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000009593 intrauterine fetal growth Effects 0.000 abstract description 3
- 230000004913 activation Effects 0.000 abstract description 2
- 230000003042 antagnostic effect Effects 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 102000003666 Placenta Growth Factor Human genes 0.000 abstract 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 88
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 86
- 235000018102 proteins Nutrition 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 51
- 150000001413 amino acids Chemical group 0.000 description 49
- TUZYXOIXSAXUGO-PZAWKZKUSA-M pravastatin(1-) Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-M 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 23
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 23
- 230000008774 maternal effect Effects 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 22
- 101000595924 Mus musculus Placenta growth factor Proteins 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 15
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 14
- 210000001161 mammalian embryo Anatomy 0.000 description 14
- 241000283707 Capra Species 0.000 description 13
- 230000036772 blood pressure Effects 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 239000013603 viral vector Substances 0.000 description 12
- 241000283690 Bos taurus Species 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 11
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- 241001494479 Pecora Species 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 210000003754 fetus Anatomy 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000035606 childbirth Effects 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 5
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 5
- 241000283073 Equus caballus Species 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 208000012766 Growth delay Diseases 0.000 description 5
- 241000711408 Murine respirovirus Species 0.000 description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 229960005370 atorvastatin Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 241000255789 Bombyx mori Species 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- 206010048554 Endothelial dysfunction Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000283086 Equidae Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 4
- 101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 description 4
- 241000208125 Nicotiana Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000282577 Pan troglodytes Species 0.000 description 4
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 235000010724 Wisteria floribunda Nutrition 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- -1 deltaU3 Proteins 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 230000008694 endothelial dysfunction Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 230000009602 intrauterine growth Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 102000050995 human FLT1 Human genes 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 229950009116 mevastatin Drugs 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000009126 molecular therapy Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 210000002993 trophoblast Anatomy 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 208000000091 Maternal Death Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000005059 placental tissue Anatomy 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 210000000143 trophectoderm cell Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100372761 Mus musculus Flt1 gene Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010054810 Placental dysplasia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WPDUROCMXHHJPU-WWPRMLFWSA-N [(1s,7s,8s,8ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,4a,7,8,8a-hexahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=CC2C=CC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 WPDUROCMXHHJPU-WWPRMLFWSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 210000001705 ectoderm cell Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 101150040383 pel2 gene Proteins 0.000 description 1
- 101150050446 pelB gene Proteins 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D19/00—Instruments or methods for reproduction or fertilisation
- A61D19/04—Instruments or methods for reproduction or fertilisation for embryo transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Definitions
- the present invention relates to a model animal of a disease such as pregnancy-induced hypertension syndrome that expresses sFLT1 specifically in the placenta, and a method for producing the model animal.
- the present invention also relates to a method for screening candidate compounds for therapeutic agents for diseases such as gestational hypertension syndrome and a pharmaceutical composition for treating diseases such as gestational hypertension syndrome.
- Pregnancy hypertension syndrome originates from placental dysfunction and is observed in approximately 5-7% of pregnant women (Lancet. 2006 Apr 1; 367 (9516): 1066-74, WHO analysis of causes of maternal death: a systematic review (Non-Patent Document 1)).
- Gestational hypertension syndrome is a major cause of maternal and infant morbidity and mortality, but the only established treatment is to terminate pregnancy and remove the placenta. Therefore, generating an appropriate animal model is of great clinical significance for understanding the etiology and developing therapeutics.
- sFLT1 is a soluble form of the VEGF receptor and antagonizes VEGF and PlGF function
- impaired angiogenic signaling is thought to cause vascular endothelial dysfunction and pregnancy hypertension syndrome (N Engl J Med. 2004 Feb 12; 350 (7): 672-83. Circulating angiogenic factors and the risk of preeclampsia. This is supported by the fact that systemic administration of adenoviral vectors (AdV-) expressing sFLT1 to pregnant rats showed glomerulosclerosis, a classic lesion of hypertension, proteinuria, and gestational hypertension syndrome. (J Clin Invest.
- sFlt1 Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
- sFLT1 is produced not in the placenta, which is the causative organ, but in the mother (mainly the liver), the pathological condition is not improved by childbirth.
- the present inventors have attempted to create a non-human animal that specifically expresses human sFLT1 in the mouse placenta using a lentiviral vector.
- the present inventors show that the model animal exhibits hypertension, placental dysfunction, intrauterine growth retardation (IUGR), glomerulosclerosis, proteinuria during pregnancy, and the symptoms improve after delivery, It was found that the symptoms were very close to the human clinical situation.
- the present inventors tried to administer pravastatin (PS) to this model animal.
- PS pravastatin
- pravastatin induces the expression of placenta-derived growth factor (PlGF) that antagonizes sFLT1, resulting in gestational hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria caused by sFLT1 Found to improve.
- PlGF placenta-derived growth factor
- the present inventors have also found that pravastatin induces ectopic expression of PlGF other than placenta.
- the present invention is based on such knowledge and relates to the following inventions.
- the non-human mammal according to [1] exhibiting symptoms of at least one disease selected from the group consisting of gestational hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria .
- the non-human mammal according to [2] obtained by the steps comprising (a) to (c) below; (A) removing the zona pellucida of the blastocyst of the non-human mammal, (B) a step of introducing a nucleic acid encoding sFLT1 specifically to the trophectoderm of the blastocyst obtained in step (a), (C) A step of transplanting the blastocyst obtained in the step (b) to a recipient.
- a method for producing a non-human mammal comprising the following steps (a) to (c): (A) removing the zona pellucida of the blastocyst of the non-human mammal, (B) a step of introducing a nucleic acid encoding sFLT1 specifically to the trophectoderm of the blastocyst obtained in step (a), (C) A step of transplanting the blastocyst obtained in the step (b) to a recipient.
- a screening method for a substance that improves symptoms of pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth delay, glomerulosclerosis and proteinuria comprising the following steps (a) to (c): (A) obtaining a non-human mammal according to any one of [1] to [3], (B) a step of administering a test substance to the non-human mammal obtained in step (a), and (c) pregnancy hypertension syndrome, placental dysfunction, intrauterine as compared with the case where no test substance is administered Selecting a substance that improves at least one symptom of fetal growth retardation, glomerulosclerosis and proteinuria.
- Treatment of at least one disease selected from the group consisting of pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria containing PlGF or a nucleic acid encoding PlGF as an active ingredient A pharmaceutical composition for use in.
- a method for treating at least one disease selected from the group consisting of pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis, and proteinuria comprising the step of administering a statin to a subject.
- At least one selected from the group consisting of pregnancy hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria comprising the step of administering to a subject PlGF or a nucleic acid encoding PlGF. How to treat the disease.
- statins in the manufacture of a pharmaceutical composition for use in the treatment of at least one disease selected from the group consisting of gestational hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria .
- PlGF or PlGF in the manufacture of a pharmaceutical composition for use in the treatment of at least one disease selected from the group consisting of gestational hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria
- a statin for use in the treatment of at least one disease selected from the group consisting of gestational hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria is a statin for use in the treatment of at least one disease selected from the group consisting of gestational hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria.
- a statin for the treatment of at least one disease selected from the group consisting of pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria.
- PlGF or a nucleic acid encoding PlGF for the treatment of at least one disease selected from the group consisting of gestational hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria.
- a PlGF induction promoter containing a statin as an active ingredient comprising a step of administering a statin to a subject.
- a method for inducing PlGF comprising a step of administering a statin to a subject.
- Use of statins in the production of PlGF inducers comprising a step of administering a statin to a subject.
- Use of statins in the production of PlGF inducers comprising a step of administering a statin to a subject.
- a statin for use in induction of PlGF comprising a statin for use induction of PlGF.
- FIG. 1 A scheme for generating a model mouse for pregnancy hypertension syndrome is shown. After removal of the zona pellucida, the blastocyst was transduced with a lentiviral vector (LV-hsFLT1) expressing human sFLT1 (hsFLT1) and then transplanted into a pseudopregnant female animal.
- the transduced trophectoderm (TE) cell line provides the main component of the placenta and persistently expresses hsFLT1. Inner cell mass, ICM.
- hsFLT1, mouse VEGF (mVEGF), and mouse PlGF (mPlGF) in maternal blood were measured with E18.5.
- C mRNA extracted from E18.5 placenta was analyzed by quantitative RT-PCR.
- Pravastatin (5 ⁇ g) was administered daily starting from E7.5 to non-pregnant and pregnant female mice not treated with viral vectors. The concentration of mPlGF in maternal blood was measured with E18.5.
- E HUVEC cells were cultured in a statin-containing medium, and human VEGF (hVEGF) and human PlGF ⁇ ⁇ (hPlGF) concentrations in the supernatant were measured 24 hours later. 293T cells were used as a control.
- the present invention relates to a non-human mammal characterized in that sFLT1 (soluble fms-like tyrosine kinase-1) is expressed specifically in the placenta.
- the non-human mammal of the present invention constitutively expresses sFLT1.
- sFLT1 expression is placenta-specific, but placenta-derived sFLT1 circulates in maternal blood.
- the placenta has a very complicated structure of maternal blood vessels and fetal blood vessels (labyrinth layer), where the blood flow of the mother and fetus is not mixed, and gas, hormones, nutrients and waste are exchanged. .
- fetal cells infiltrate into some maternal blood vessels. Because sFLT1 made from placental fetal cells is secreted extracellularly, it is collected through maternal blood vessels in the placenta and circulates in maternal blood through the umbilical cord.
- the non-human mammal of the present invention exhibits symptoms of diseases such as pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth delay, glomerulosclerosis, proteinuria and the like.
- sFLT1 expression is placenta-specific, but placenta-derived sFLT1 circulates in the maternal blood. Furthermore, it follows a course very similar to human pathology, such as showing improvement in the symptoms of these diseases after childbirth.
- the non-human mammal of the present invention exhibits symptoms of diseases such as pregnancy hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis, proteinuria, etc. while having a placenta. And when the placenta is removed from the body with childbirth, these symptoms are improved.
- a non-human mammal of the present invention is useful as a model animal for diseases such as pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth delay, glomerulosclerosis, and proteinuria.
- the non-human mammal of the present invention is used in a screening method for drug candidate compounds for the treatment and prevention of diseases such as pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis, and proteinuria. can do.
- diseases such as pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis, proteinuria are caused by sFLT1.
- FLT1 membrane-type fms-like tyrosine kinase 1 is a membrane protein known as a specific receptor for Vascular endothelial growth factor (VEGF) or placental growth factor (PlGF).
- VEGF Vascular endothelial growth factor
- PlGF placental growth factor
- sFLT1 soluble fms-like tyrosine kinase 1 is a FLT1 that does not have a transmembrane domain and is a soluble protein known as a specific receptor for Vascular endothelial growth factor (VEGF) or placental growth factor (PlGF) .
- the sFLT1 of the present invention all or part of the transmembrane domain is removed from the full-length FLT1, and the sFLT1 is not limited as long as it is soluble and can form a dimer.
- causes of removal of the transmembrane domain include, but are not limited to, protein cleavage, mRNA cleavage, or exon usage.
- the nucleotide sequence and amino acid sequence of the transmembrane domain of human FLT1 identified using SOSUI are shown in SEQ ID NOs: 19 and 20, and the nucleotide sequence and amino acid sequence of the transmembrane domain of mouse FLT1 are shown in SEQ ID NOs: 21 and 22, respectively.
- the sequence of the transmembrane domain is not limited to these.
- those skilled in the art can use a known program such as SOSUI (http://bp.nuap.nagoya-u.ac.jp/sosui/) to transmembrane in FLT1 derived from various animal species. Domains can be easily identified.
- a person skilled in the art can specify a transmembrane domain based on known literature.
- Flt-1 has seven to seven immunoglobulin-like domains outside the cell, whereas sFlt-1 has the first to sixth of these seven domains and the 5 ′ region of intron 13
- 31 amino acids encoded by Shibuya, Cell Structure and Function, 26, 25-35 (2001)
- 31 amino acids encoded by the 5 ′ region of intron 13 are highly conserved among mammals.
- the transmembrane domain is encoded by exon 16 of the FLT gene, and it is known that when exon 16 of human FLT1 is actually deleted, it becomes soluble (Molecular and Cellular Biology, January 2005, p. 346-354, Vol. 25, No.
- nucleic acid encoding human sFLT1 examples include, but are not limited to, the following.
- NCBI Reference Sequence DNA having a base sequence obtained by removing the base sequence of the transmembrane domain from the base sequence specified by NM_002019.4
- human sFLT1 protein examples include, but are not limited to, the following.
- a protein having an amino acid sequence encoded by the DNA described in (1) or (2) above (4) Protein having an amino acid sequence (amino acid sequence described in SEQ ID NO: 2) specified by GenBank: U01134.1 and GenBank: AAC50060.1 (5) NCBI Reference Sequence: a protein having an amino acid sequence obtained by removing the amino acid sequence of the transmembrane domain from the amino acid sequence specified by NP_002010.2
- the sFLT1 of the present invention is not limited to human-derived sFLT1.
- the sFLT1 of the present invention includes sFLT1 derived from chimpanzee, mouse, rat, dog, cow, horse, pig, sheep and the like. SFLT1 derived from these animals also has a structure in which the transmembrane domain is removed from full-length FLT1.
- the nucleic acid encoding chimpanzee-derived sFLT1 includes, but is not limited to, a nucleic acid having a base sequence obtained by removing the base sequence of the transmembrane domain from the base sequence specified by NCBI Reference Sequence: XM_509605.2.
- the chimpanzee-derived sFLT1 protein includes a protein having an amino acid sequence encoded by the nucleic acid, and a protein having an amino acid sequence obtained by removing the amino acid sequence of the transmembrane domain from the amino acid sequence specified by NCBI Reference Sequence XP_509605.2 However, it is not limited to these.
- mouse-derived sFLT1 As a nucleic acid encoding mouse-derived sFLT1, the nucleotide sequence of the transmembrane domain was removed from the nucleic acid having the nucleotide sequence specified by GenBank: BC029674.1, the nucleotide sequence specified by NCBI Reference: Sequence: NM_010228.3 Examples include, but are not limited to, nucleic acids having a base sequence.
- the mouse-derived sFLT1 protein has a protein having an amino acid sequence encoded by the nucleic acid, or an amino acid sequence obtained by removing the amino acid sequence of the transmembrane domain from the amino acid sequence specified by NCBI Reference Sequence: NP_034358.2 Examples include, but are not limited to proteins.
- nucleic acid encoding rat-derived sFLT1 examples include, but are not limited to, DNA having a base sequence obtained by removing the base sequence of the transmembrane domain from the base sequence specified by NCBI Reference Sequence: NM_019306.1.
- the rat-derived sFLT1 protein has a protein having an amino acid sequence encoded by the nucleic acid or an amino acid sequence obtained by removing the amino acid sequence of the transmembrane domain from the amino acid sequence specified by NCBINCReference Sequence: NP_062179.1 Examples include, but are not limited to proteins.
- nucleic acids encoding dog-derived sFLT1 include, but are not limited to, nucleic acids having a base sequence obtained by removing the base sequence of the transmembrane domain from the base sequence specified by NCBI Reference Sequence: XM_534520.2.
- the dog-derived sFLT1 protein has a protein having an amino acid sequence encoded by the nucleic acid, or an amino acid sequence obtained by removing the amino acid sequence of the transmembrane domain from the amino acid sequence specified by NCBI Reference Sequence: XP_534520.2 Examples include, but are not limited to proteins.
- nucleic acid encoding bovine-derived sFLT1 examples include, but are not limited to, a nucleic acid having a base sequence obtained by removing the base sequence of the transmembrane domain from the base sequence specified by NCBI Reference Sequence: XM_001249768.2.
- the bovine-derived sFLT1 protein has a protein having an amino acid sequence encoded by the nucleic acid, or an amino acid sequence obtained by removing the amino acid sequence of the transmembrane domain from the amino acid sequence specified by NCBI Reference Sequence: XP_001249768.2. Examples include, but are not limited to proteins.
- Examples of the nucleic acid encoding horse-derived sFLT1 include, but are not limited to, a nucleic acid having a base sequence obtained by removing the base sequence of the transmembrane domain from the base sequence specified by NCBI Reference Sequence: XM_001492325.2.
- the horse-derived sFLT1 protein has a protein having an amino acid sequence encoded by the nucleic acid or an amino acid sequence obtained by removing the amino acid sequence of the transmembrane domain from the amino acid sequence specified by NCBI® Reference: Sequence: XP_001492375.1 Examples include, but are not limited to proteins.
- nucleic acid encoding pig-derived sFLT1 examples include, but are not limited to, a nucleic acid having a base sequence obtained by removing the base sequence of the transmembrane domain from the base sequence specified by NCBI Reference Sequence: XM_001925740.1.
- the swine-derived sFLT1 protein has a protein having an amino acid sequence encoded by the nucleic acid, or an amino acid sequence obtained by removing the amino acid sequence of the transmembrane domain from the amino acid sequence specified by NCBI Reference Sequence: XP_001925775.1 Examples include, but are not limited to proteins.
- nucleic acid encoding sheep-derived sFLT1 examples include, but are not limited to, a nucleic acid having a base sequence obtained by removing the base sequence of the transmembrane domain from the base sequence specified by GenBank: AF233077.1.
- sFLT1 protein derived from sheep a protein having an amino acid sequence encoded by the nucleic acid, a protein having an amino acid sequence obtained by removing the amino acid sequence of the transmembrane domain from the amino acid sequence specified by GenBank: AAF60281.1, etc.
- the nucleic acid encoding sFLT1 includes “DNA encoding sFLT1” and “RNA encoding sFLT1”.
- gestational hypertension syndrome refers to a case where hypertension is observed after 20 weeks of gestation and 12 weeks after delivery, or when hypertension is accompanied by proteinuria, and these symptoms are merely contingent complications of pregnancy. It means something that is not due to. As pregnancy hypertensive syndrome progresses, it causes placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria.
- a non-human mammal that expresses sFLT1 of the present invention in a placenta-specific manner can be produced by the following steps (a) to (c).
- C A step of transplanting the blastocyst obtained in the step (b) to a recipient.
- the recipient is preferably a non-human mammal.
- Non-human animals obtained by such processes exhibit symptoms of diseases such as pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth delay, glomerulosclerosis, and proteinuria.
- a blastocyst is an embryo whose cleavage period is over in the early development of a mammal.
- Mammalian eggs are non-yellow eggs that form all-divided blastomeres, but in the 32-cell stage, they are divided into trophectoderm that wraps the outside of the mass and the inner cell mass inside. The inner cell mass will become the fetal body in the future, and the trophectoderm will differentiate into the placenta in the future.
- the nucleic acid encoding sFLT1 is specifically introduced into trophectoderm cells that form the outermost layer of the blastocyst.
- Non-human animals include, but are not limited to, humans, mice, rats, rabbits, guinea pigs, hamsters, dogs, cats, cows, horses, pigs, goats and sheep.
- a blastocyst can be produced by the following method. For example, eggs and sperm are collected from any non-human mammal and fertilized by techniques known to those skilled in the art.
- a blastocyst can be prepared by culturing the obtained fertilized egg for 96 hours in a method known to those skilled in the art, for example, in a kSOM medium. Further, a method by those skilled in the art usually performed (e.g., Manipulating the mouse embryo, a laboratory manual, 3 rd edition, p201-203, The method according to Cold Spring Harbor Laboratory Press) according, blastocysts by removing directly from the animal May be obtained.
- the zona pellucida obtained as described above is then removed.
- Embryos earsly preimplantation embryos
- a zona pellucida which is an extracellular matrix around them to protect against infections such as viruses.
- this zona pellucida is removed.
- the removal of the zona pellucida can be performed by a known method. For example, it can be performed by acid treatment, enzyme treatment, physical treatment, or the like. Examples of acidic treatment, treatment with an acidic Tyrode (Manipulating the mouse embryo, a laboratory manual, 3 rd edition, p485-486, Cold Spring Harbor Laboratory Press) and the like. For example, an acidic tyrode solution (pH 2.3 to 2.5) is sucked into a micropipette in advance and gently sprayed onto the fixed embryo to dissolve a part of the zona pellucida. Alternatively, the zona pellucida is dissolved by immersing the embryo in an acidic tyrode solution.
- the removal of the zona pellucida by the enzyme treatment method includes treatment with Pronase (Calbiochem 537088, Sigma P5147) and the like. For example, leave the embryo in the Pronase 0.5% solution until the zona pellucida has dissolved. After the zona pellucida is melted, by washing well the embryos in a medium, it is possible to obtain the zona pellucida has been removed blastocyst (Manipulating the mouse embryo, a laboratory manual, 3 rd edition, p731, Cold Spring Harbor Laboratory Press).
- the removal of the zona pellucida in the present invention may be performed by a physical method.
- a physical removal method the zona pellucida incision method (Hum. Reprod., 5: 7-13, 1990), laser (Hum. Reprod., 15 : 1061-1064, 2000) and piezo micromanipulators (Developmental Biology, 250: 348-357, 2002).
- the removal of the zona pellucida can be performed by the above method.
- the method for removing the zona pellucida in the present invention is not limited to these, and includes any method capable of removing the zona pellucida.
- a nucleic acid encoding sFLT1 is introduced into the blastocyst from which the zona pellucida has been removed.
- a method for introducing a nucleic acid encoding sFLT1 into a blastocyst from which the zona pellucida has been removed is not particularly limited.
- a vector having a nucleic acid encoding sFLT1 is introduced into a blastocyst. A method is mentioned.
- Examples of the vector having a nucleic acid encoding sFLT1 to be introduced into a blastocyst include a viral vector.
- examples of viral vectors include DNA viral vectors and RNA viral vectors.
- DNA viral vectors include, but are not limited to, adenovirus vectors and adeno-associated virus vectors.
- examples of RNA viral vectors include retroviral vectors (Molecular Therapy 2003, 8; 666-673) such as lentiviral vectors (Molecular Therapy 2003, 8; 666-673).
- a nucleic acid introduction reagent such as HVJ liposome or Lipofectamine can also be used.
- HVJ hemagglutinating virus of Japan
- HVJ hemagglutinating virus of Japan
- HMG-1 DNA-binding protein HMG-1 to efficiently use genes and oligonucleotides sealed in liposomes. It is a vector that can be introduced into various organs of a living body.
- a preferred vector is a lentiviral vector.
- Lentivirus is a genus of retroviruses and is a human, monkey, cat, bovine immunodeficiency virus.
- the viral gene structure has several types of regulatory genes.
- a lentiviral vector prepared by modifying a lentivirus can integrate a foreign gene into the chromosome, so long-term expression of the transgene can be expected, and unlike other retroviral vectors, it has a nuclear translocation signal and is non-dividing. Gene transfer into cells is possible.
- the lentiviral vectors used in the present invention include all lentiviral vectors having at least LTR, RRE, and GAG.
- the lentiviral vector used for the production of the non-human mammal of the present invention is only required to have such a condition as a minimum, but it has another gene such as deltaU3, PPT, WPRE as plus alpha. Also good.
- Such a lentiviral vector is also a preferred viral vector as a lentiviral vector used in the method of the present invention.
- a particularly preferred embodiment of the lentiviral vector used in the present invention is a lentiviral vector having LTR (deltaU3), GAG, RRE, PPT, and WPRE.
- LTR deltaU3
- GAG GAG
- RRE GAG
- PPT PPT
- WPRE WPRE
- a typical example of a lentiviral vector having such a structure is a vector obtained by replacing the GFP portion of the GFP viral vector disclosed in the literature Molecular Therapy 2003, 8; 666-673 with the target cDNA. The structure and construction method of this vector are disclosed in the above-mentioned literature.
- the amount and timing of introduction of a nucleic acid encoding sFLT1 into a blastocyst is not particularly limited, but a recipient transplanted with a blastocyst into which sFLT1 has been introduced has symptoms of pregnancy hypertension syndrome. It is preferable to introduce it at an amount and timing to be presented.
- the dose is preferably 10-1000 ng-p24 / ml, more preferably 20-500 ng-p24 / ml, and still more preferably 100-500 ng-p24 / ml, but is not limited thereto.
- the timing for introducing the nucleic acid encoding sFLT1 into the blastocyst is preferably before implantation.
- Infection of a lentiviral vector having a nucleic acid encoding sFLT1 into a blastocyst is performed by, for example, mixing a solution containing a lentiviral vector having a nucleic acid encoding sFLT1 with a blastocyst from which the zona pellucida has been removed. Perform by leaving it for 5 hours.
- a lentiviral vector having a nucleic acid encoding sFLT1 can be specifically introduced into trophectoderm.
- the introduction of the nucleic acid encoding sFLT1 into the blastocyst from which the zona pellucida has been removed may be performed by acting a nucleic acid introduction reagent.
- the nucleic acid introduction reagent in the present invention refers to any reagent capable of introducing a nucleic acid encoding sFLT1 into a blastocyst. Examples of such nucleic acid introduction reagents include, but are not limited to, (Lipofectoamine 2000, Invitrogen) fect (Effectene, Qiagen) (FuGene, Roche).
- the nucleic acid encoding sFLT1 includes, but is not limited to, DNA encoding sFLT1 and RNA encoding sFLT1.
- the form of the nucleic acid encoding sFLT1 to be introduced may be a form of DNA, RNA, cDNA, mRNA or artificial nucleic acid.
- DNA, RNA, cDNA, and mRNA also include derivatives thereof.
- Examples of the artificial nucleic acid include, but are not limited to, DNA, RNA, cDNA, mRNA, or derivatives thereof whose sugar chain structure is modified.
- the nucleic acid encoding sFLT1 to be introduced may be naked DNA or may be introduced into a vector.
- the vector used in the present invention is for efficiently expressing a nucleic acid encoding sFLT1, such as a transcription initiation region or transcription termination region that functions in an expression host.
- a polynucleotide region may be included.
- Nucleic acids encoding sFLT1 can be easily obtained by those skilled in the art.
- various biological samples such as placental tissue, trophoblast stem cells and differentiated cells thereof can be used as raw materials, and can be isolated from nature based on their physicochemical properties. Alternatively, it may be chemically synthesized based on known sequence information.
- the nucleic acid encoding sFLT1 includes various animal homologous genes.
- the “homologous gene” encodes a polynucleotide containing the nucleotide sequence set forth in SEQ ID NO: 1 or a protein having a biological function equivalent to the transcription or translation product of the polynucleotide in various animals. Refers to a polynucleotide.
- a polynucleotide that specifically hybridizes to a polynucleotide encoding sFLT1 for example, the nucleotide sequence set forth in SEQ ID NO: 1 or a part thereof as a probe, or to a polynucleotide encoding sFLT1
- a polynucleotide encoding sFLT1 it is usually possible to isolate a polynucleotide encoding sFLT1 from various animal cells and tissues (for example, placental tissue, trophoblast stem cells and differentiated cells thereof) using as a primer.
- a hybridization reaction is usually carried out under stringent conditions.
- stringent hybridization conditions Those skilled in the art can appropriately select stringent hybridization conditions.
- One example is pretreatment overnight at 42 ° C. in a hybridization solution containing 25% formamide, 50% formamide under more severe conditions, 4 ⁇ SSC, 50 mM Hepes pH 7.0, 10 ⁇ Denhardt's solution, 20 ⁇ g / ml denatured salmon sperm DNA. After hybridization, a labeled probe is added and hybridization is performed by incubating overnight at 42 ° C.
- the cleaning solution and temperature conditions for the subsequent cleaning are about 1xSSC, 0.1% SDS, 37 ° C, more severe conditions are about 0.5xSSC, 0.1% SDS, 42 ° C, and more severe conditions are about 0.2xSSC. , 0.1% SDS, about 65 ° C. ”.
- isolation of DNA having high homology with the probe sequence can be expected as the conditions for washing hybridization are more severe.
- combinations of the above SSC, SDS, and temperature conditions are exemplary, and those skilled in the art will recognize the above or other factors that determine the stringency of hybridization (eg, probe concentration, probe length, hybridization reaction). It is possible to achieve the same stringency as above by appropriately combining the time and the like.
- DNA with higher homology can be isolated under conditions of higher stringency, for example, 6M urea, 0.4% SDS, 0.1 ⁇ SSC.
- High homology refers to sequence identity of at least 50% or more, preferably 70% or more, more preferably 90% or more, and most preferably 95% or more of the entire amino acid sequence.
- the number of amino acids to be mutated is usually within 30 amino acids, preferably within 15 amino acids, more preferably within 5 amino acids, still more preferably within 3 amino acids, and even more preferably 2 amino acids. Is within.
- the identity of amino acid sequences and base sequences is determined using the algorithm BLAST (Proc. Natl. Acad. Sci. USA 87: 2264-2268, 1990, Proc Natl Acad Sci USA 90: 5873, 1993) by Carlin and Arthur. can do.
- the polynucleotide encoding sFLT1 in the present invention is not particularly limited, but preferably derived from human, mouse, rat, rabbit, guinea pig, hamster, dog, cat, cow, horse, pig, goat and sheep. Polynucleotides, particularly preferably polynucleotides derived from humans.
- the blastocyst is transplanted into a recipient.
- the recipient is preferably a non-human animal.
- the recipient is preferably the same animal as the animal from which the blastocyst is derived, or the same kind of animal.
- Transplantation into recipient blastocysts is that those skilled in the art can be performed normally (Manipulating the mouse embryo, a laboratory manual, 3 rd edition, p263-271, Cold Spring Harbor Laboratory Press, cattle embryo transfer, Hafetsu livestock Reproductive Science 5th edition, translated by Shigeo Yoshida, Junji Masaki Akira Iriya, Nishimura Shoten 1992).
- Non-human animals produced in the present invention are not particularly limited, and examples thereof include mice, rats, rabbits, guinea pigs, hamsters, dogs, cats, cows, horses, pigs, goats and sheep. .
- nucleic acid encoding sFLT1 was specifically introduced into the trophectoderm of the blastocyst by the method of the present invention depends on the PCR method for amplifying the transgene and the expression of reporter genes such as EGFP and lacZ. It can be determined by using a method known to those skilled in the art, such as detection by a method such as
- the present invention relates to a method for producing a non-human mammal that expresses sFLT1 in a placenta-specific manner including such steps.
- the present invention also relates to a method for producing a blastocyst in which a nucleic acid encoding sFLT1 is specifically introduced into trophectoderm cells.
- the present invention also relates to at least one disease selected from the group consisting of pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine fetal growth retardation, glomerulosclerosis and proteinuria, comprising the following steps (a) to (c):
- the present invention relates to a method for screening a substance that improves symptoms.
- step (A) obtaining a non-human mammal that expresses sFLT1 described herein in a placenta-specific manner, (B) a step of administering a test substance to the non-human mammal obtained in step (a), and (c) pregnancy hypertension syndrome, placental dysfunction, intrauterine as compared with the case where no test substance is administered
- step (B) a step of selecting a substance that improves symptoms of at least one disease selected from the group consisting of fetal growth retardation, glomerulosclerosis and proteinuria.
- the substance obtained by the screening method of the present invention is a candidate compound for a therapeutic agent for at least one disease selected from the group consisting of pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria.
- a screening method for a substance that improves symptoms of at least one disease selected from the group consisting of pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria is disclosed as pregnancy hypertension syndrome, placental function, It can also be expressed as a screening method for a candidate compound for a therapeutic agent for at least one disease selected from the group consisting of failure, intrauterine growth retardation, glomerulosclerosis and proteinuria.
- test substances include natural compounds, organic compounds, inorganic compounds, proteins, peptides, and other single compounds, as well as compound libraries, gene library expression products, cell extracts, cell culture supernatants, and fermentation microorganisms. Examples include, but are not limited to, products, marine organism extracts, plant extracts, and the like.
- test compound administered to a non-human mammal in which sFLT1 of the present invention is expressed specifically in the placenta
- the test compound is a protein
- a viral vector having a gene encoding the protein is constructed, and the gene is introduced into the genetically modified non-human mammal of the present invention using its infectivity. It is also possible.
- the test substance is a symptom of at least one disease selected from the group consisting of pregnancy hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria. It is determined whether or not it has been improved.
- the symptom of at least one disease selected from the group consisting of pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria is improved.
- the test substance is a group consisting of gestational hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria It is determined that the symptom of at least one disease selected is improved.
- PlGF mRNA can be measured by Northern blot, quantitative RT-PCR, and microarray analysis.
- the blood concentration can be measured by Western blot or ELISA.
- blood pressure is measured or albumin / creatinine in urine is measured, and when these values decrease, it is determined that the test substance has improved the symptoms of pregnancy-induced hypertension syndrome. Furthermore, if it is determined that glomerulosclerosis has been improved by observing the pathological section of the kidney, or if it is determined that vascular dysplasia has been improved by observing the pathological section of the placenta, the weight of the reduced fetus or placenta is recovered. It is determined that the symptoms have been improved.
- the present invention also provides a medicament for treating at least one disease selected from the group consisting of pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis, and proteinuria, comprising statin as an active ingredient.
- the present invention relates to a composition (therapeutic agent). Further, the present invention is selected from the group consisting of pregnancy hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria containing PlGF (placental growth factor) or a nucleic acid encoding PlGF as an active ingredient.
- a pharmaceutical composition (therapeutic agent) for treating at least one disease is provided.
- statin known as a therapeutic agent for hyperlipidemia
- a non-human model mammal developed by the present inventors
- the present inventors have resulted in pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine fetal growth delay, thread It was confirmed that symptoms of spherical sclerosis and proteinuria improved. It was also confirmed that PlGF expression was induced by statin administration. Therefore, nucleic acids (DNA, RNA) encoding statins, PlGF, and PlGF are considered useful as therapeutic agents for pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis, and proteinuria.
- Statins have the following effects in humans and non-human animals into which sFLT1 has been introduced specifically in the placenta. • Significantly reduce maternal blood levels of sFLT1. -Does not affect maternal blood concentration of VEGF. • Significantly induce PlGF mRNA levels. It increases about 5 times, especially in the placenta. ⁇ Significantly induces maternal blood levels of PlGF. ⁇ Repair placental formation disorder. ⁇ Recover intrauterine growth restriction. ⁇ Improve high blood pressure. ⁇ Improve renal dysfunction. Statins also significantly increase circulating PlGF in wild pregnant female and non-pregnant animals. It does not reduce blood pressure in normal pregnant female animals.
- Pravastatin and atorvastatin also induce the production of PlGF in human umbilical cord blood endothelial cells (HUVEC).
- PlGF has the following effects in non-human animals into which sFLT1 has been specifically introduced. ⁇ Improve hypertension by depleting sFLT1 in maternal blood. ⁇ Improve renal dysfunction. ⁇ Repair placental formation disorder. ⁇ Recover intrauterine growth restriction.
- HMG-CoA reductase inhibitors are generic names for drugs that lower cholesterol levels in the blood by inhibiting the action of HMG-CoA reductase.
- mevastatin aka compactin, chemical name: [(1S, 7S, 8S, 8aR) -8- [2-[(2R, 4R) -4-hydroxy-6-oxooxan-2-yl] ethyl] -7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S) -2-methylbutanoate, [(1S, 7S, 8S, 8aR) -8- [2-[(2R , 4R) -4-hydroxy-6-oxooxan-2-yl] ethyl] -7-methyl-1,2,4a, 7,8,8a-hexahydronaphthalen-1-yl] (2S) -2-methylbutanoate, 8- [2- (4-hydroxy-6-oxoxan-2-y
- statins other than mevastatin can be synthesized by those skilled in the art according to the description in JP-T-2009-538831.
- mevastatin can be obtained by those skilled in the art by the method described in Journal of Lipid Research Volume 33, 1992, for example.
- pravastatin can be purchased from Cayman chemical and atorvastatin from Tronto Research Chemicals. Furthermore, it can be obtained from many pharmaceutical companies as a prescription drug.
- the PlGF gene and the protein encoded by the gene are known.
- the mouse PlGF gene and the protein encoded by the gene are known as GenBank: BC016567.1
- the human PlGF gene and the protein encoded by the gene are known as GenBank: BC001422.2.
- the base sequence of the mouse PlGF gene is shown in SEQ ID NO: 3
- the protein encoded by the gene is shown in SEQ ID NO: 4.
- the base sequence of the human PlGF gene is shown in SEQ ID NO: 5
- the protein encoded by the gene is shown in SEQ ID NO: 6.
- the PlGF gene and the protein encoded by the gene are also known in chimpanzees, rats, dogs, cows, horses, pigs, sheep and the like. Each accession number is shown below.
- nucleic acid encoding PlGF in the agent of the present invention include “DNA encoding PlGF” and “RNA encoding PlGF”.
- the form of “DNA encoding PlGF” is not particularly limited, and may be genomic DNA, cDNA, synthetic DNA, or a vector containing these DNAs.
- “PlGF” in the pharmaceutical composition (therapeutic agent) of the present invention can be prepared as a recombinant protein using a known genetic recombination technique in addition to a natural protein.
- “PlGF” in the pharmaceutical composition (therapeutic agent) of the present invention is not particularly limited to the organism from which it is derived. When used for treatment or prevention of human diseases, it is preferably derived from mammals, and most preferably derived from humans. Natural proteins can be prepared by, for example, a method using affinity chromatography using an antibody against PlGF to an extract of a tissue such as a placenta considered to express PlGF.
- a recombinant protein can be prepared by a person skilled in the art by a known method, for example, as a recombinant polypeptide.
- the recombinant polypeptide can be obtained by, for example, incorporating a nucleic acid encoding PlGF into an appropriate expression vector, and introducing this into an appropriate host cell, collecting the transformant, obtaining an extract, ion exchange, It can be purified and prepared by subjecting to chromatography such as reverse phase, gel filtration, or affinity chromatography in which an antibody against PlGF is immobilized on the column, or by further combining a plurality of these columns.
- a host cell eg, animal cell or E.
- the recombinant polypeptide can be purified using a glutathione column or a nickel column.
- the vector for example, when Escherichia coli is used as a host, the vector is amplified in Escherichia coli in order to amplify it in large quantities in Escherichia coli (for example, JM109, DH5 ⁇ , HB101, XL1Blue) and the like.
- Escherichia coli for example, JM109, DH5 ⁇ , HB101, XL1Blue
- an ori and a transformed gene of E. coli transformed (for example, any drug (drug resistance gene that can be distinguished by ampicillin, tetracycline, kanamycin, chloramphenicol)).
- examples include M13 vectors, pUC vectors, pBR322, pBluescript, pCR-Script, etc.
- an expression vector is particularly useful.
- the host is E. coli such as JM109, DH5 ⁇ , HB101, XL1-Blue Promoters that can be expressed efficiently in E. coli, such as the lacZ promoter (Ward et al., Nature (1989) 341, 544-546; FASEB J.
- Such vectors include pGEX-5X-1 (Pharmacia), “QIAexpress system "(Qiagen), pEGFP, or pET.
- the vector may contain a signal sequence for polypeptide secretion.
- the pelB signal sequence Lei, S. P. et al J. Bacteriol. (1987) 169, 4379
- Introduction of a vector into a host cell can be performed using, for example, a calcium chloride method or an electroporation method.
- vectors for producing PlGF include mammalian-derived expression vectors (for example, pcDNA3DNA (manufactured by Invitrogen), pEGF-BOS (Nucleic Acids. Res.1990, 18 (17) , p5322), pEFp, pCDM8), insect cell-derived expression vectors (eg “Bac-to-BACculbaculovairus expression system” (manufactured by Gibco BRL), pBacPAK8), plant-derived expression vectors (eg pMH1, pMH2), animals Expression vectors derived from viruses (eg, pHSV, pMV, pAdexLcw), expression vectors derived from retroviruses (eg, pZIPneo), expression vectors derived from yeast (eg, “Pichia Expression Kit” (Invitrogen), pNV11, SP -Q01), expression vectors derived from Bacillus subtilis (for example
- a promoter necessary for expression in the cells such as the SV40 promoter (Mulligan et al., Nature (1979) 277, 108), It is essential to have MMLV-LTR promoter, EF1 ⁇ promoter (Mizushima et al., Nucleic Acids Res. (1990) 18, 5322), CMV promoter, etc., and genes for selecting transformation into cells (for example, More preferably, it has a drug resistance gene that can be discriminated by a drug (neomycin, G418, etc.).
- Examples of such a vector include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13.
- Examples of the system for producing a polypeptide in vivo include a production system using animals and a production system using plants. A nucleic acid encoding PlGF is introduced into the animal or plant, and PlGF is produced in the body of the animal or plant and recovered. When animals are used, there are production systems using mammals and insects. As mammals, goats, pigs, sheep, mice and cows can be used (Vicki Glaser, SPECTRUM Biotechnology Applications, 1993). Moreover, when using a mammal, a transgenic animal can be used.
- a nucleic acid encoding PlGF is prepared as a fusion gene with a gene encoding a polypeptide inherently produced in milk such as goat ⁇ casein.
- a DNA fragment containing the fusion gene is injected into a goat embryo, and the embryo is transferred to a female goat.
- PlGF can be obtained from the milk produced by a transgenic goat born from a goat that has received the embryo or its progeny. Hormones may be used in transgenic goats as appropriate to increase milk yield containing polypeptides produced from transgenic goats (Ebert, KM et al., Bio / Technology (1994) 12, 699-702 ).
- silkworms can be used as insects.
- PlGF can be obtained from the body fluid of this silkworm by infecting a silkworm with a baculovirus inserted with a nucleic acid encoding PlGF (Susumu, M. et al., Nature (1985) 315, 592). -594).
- a nucleic acid encoding PlGF is inserted into a plant expression vector, for example, pMON ⁇ ⁇ 530, and this vector is introduced into a bacterium such as Agrobacterium tumefaciens.
- the bacteria can be infected with tobacco, for example Nicotiana tabacum, and PlGF can be obtained from the leaves of this tobacco (Julian K.-C. Ma et al., Eur. J. Immunol. (1994) 24, 131-138).
- PlGF thus obtained can be isolated from the inside of the host cell or outside the cell (such as a medium) and purified as a substantially pure and homogeneous polypeptide. Separation and purification of polypeptides may be carried out using separation and purification methods used in usual polypeptide purification, and are not limited in any way. For example, chromatography column, filter, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization, etc. are appropriately selected, When combined, polypeptides can be separated and purified.
- the modification can be arbitrarily added or the peptide can be partially removed by allowing an appropriate protein modifying enzyme to act on the PlGF of the present invention before or after purification.
- protein modifying enzymes include trypsin, chymotrypsin, lysyl endopeptidase, protein kinase, glucosidase and the like.
- the subject to which the pharmaceutical composition (therapeutic agent) of the present invention is administered is a mammal.
- Mammals include, but are not limited to, humans, mice, rats, rabbits, guinea pigs, hamsters, dogs, cats, cows, horses, pigs, goats and sheep.
- the therapeutic agent can be administered orally or parenterally, but is preferably administered parenterally, specifically, an injection form, a nasal administration form, a pulmonary administration form, or a transdermal administration. Examples include molds.
- the injection form it can be administered systemically or locally by, for example, intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, or the like.
- a viral vector such as a retrovirus, adenovirus, or Sendai virus
- a non-viral vector such as a liposome
- administration methods include in vivo methods and ex vivo methods.
- the therapeutic agent of the present invention can also be administered as a drug formulated by a known pharmaceutical method.
- it can be used in the form of a sterile solution with water or other pharmaceutically acceptable liquid, or an injection of suspension.
- a pharmacologically acceptable carrier or medium specifically sterilized water, physiological saline, emulsifier, suspending agent, surfactant, stabilizer, vehicle, preservative, etc. It is envisaged to formulate by blending in the unit dosage form required for recognized pharmaceutical practice. The amount of active ingredient in these preparations is such that an appropriate volume within the indicated range can be obtained.
- Sterile compositions for injection can be formulated according to normal pharmaceutical practice using a vehicle such as distilled water for injection.
- Aqueous solutions for injection include, for example, isotonic solutions containing physiological saline, glucose and other adjuvants such as D-sorbitol, D-mannose, D-mannitol and sodium chloride, and suitable solubilizers such as Alcohols, specifically ethanol, polyalcohols such as propylene glycol, polyethylene glycol, nonionic surfactants such as polysorbate 80 TM and HCO-50 may be used in combination.
- suitable solubilizers such as Alcohols, specifically ethanol, polyalcohols such as propylene glycol, polyethylene glycol, nonionic surfactants such as polysorbate 80 TM and HCO-50 may be used in combination.
- the oily liquid include sesame oil and soybean oil, which may be used in combination with benzyl benzoate or benzyl alcohol as a solubilizing agent.
- buffer for example, phosphate buffer, sodium acetate buffer, a soothing agent, for example, procaine hydrochloride, stabilizer, for example, benzyl alcohol, phenol, antioxidant.
- a soothing agent for example, procaine hydrochloride
- stabilizer for example, benzyl alcohol, phenol, antioxidant.
- the dose can be appropriately selected depending on the age and symptoms of the patient. For example, it is possible to select within a range of 0.0001 mg to 1000 mg per kg of body weight at a time. Alternatively, for example, the dose can be selected within the range of 0.001 to 100,000 mg / body per patient.
- the drug of the present invention is not limited to these doses.
- the therapeutic agent of the present invention is preferably administered daily from the early stage of hypertension. More specifically, for example, in the case of humans, it is preferable to administer daily from the 20th week of pregnancy or before. For example, in the case of mice, it is preferable to administer daily from the 13th day, more preferably from the 10th day, and even more preferably from the 7th day.
- the therapeutic agent of the present invention is more preferably administered daily before the onset of hypertension. It should be noted that all prior art documents cited in the present specification are incorporated herein by reference.
- Mouse PlGF (mPlGF) cDNA was amplified by RT-PCR from E13.5 placenta with primers 5'-aagaattcgccaccatgctggtcatgaagctgttc-3 '(SEQ ID NO: 9) and 5'-ttctcgagtcacgggtggggttcctcag-3' (SEQ ID NO: 10).
- mPlGF Mouse PlGF
- primers 5′-aagtgtgacgttgacatccg-3 ′ (SEQ ID NO: 11) and 5′-gatccacatctgctggaagg-3 ′ (SEQ ID NO: 12) are used for amplification of mActb
- 5′-ggctgagcataactaaatctgcc-3 ′ (SEQ ID NO: 13).
- 5′-ggaatgacgagctcccttcctttca-3 ′ were used for amplification of hsFLT1.
- primers 5′-catccgtaaagacctctatgccaac-3 ′ (SEQ ID NO: 15) and 5′-atggagccaccgatccaca-3 ′ (SEQ ID NO: 16) were used for amplification of mActb, and 5′-tgctgggaacaactcaacag-3 ′ (SEQ ID NO: 17).
- 5′-cctcatcagggtattcatcca-3 ′ SEQ ID NO: 18
- lentiviral vector plasmid pLV-EGFP based on the lentiviral vector HIV-I has already been described (Nat Biotechnol. 2007 Feb; 25 (2): 233-7.).
- Other lentiviral vector plasmids pLV-hsFLT1 and pLV-mPlGF were prepared by exchanging EGFP cDNA for hsFLT1 and mPlGF cDNA, respectively.
- Vesicular stomatitis virus glycoprotein pseudotype lentiviral vector was generated and the p24 gag antigen concentration was determined as previously described (Nat Genet. 2000 Jun; 25 (2): 217-22.).
- mice and lentivirus-transduced wild type B6D2F1 females were over-ovulated with human chorionic gonadotropin (5 units) 48 h after intraperitoneal injection of serum gonadotropin (5 units) in pregnant mares, followed by wild type B6D2 F1 males Mated with animals.
- a 4-cell stage embryo was collected from 2 cells from a female animal 1.5 days after mating and incubated in kSOM medium (erbach BOR 1994) for 2 days to obtain a blastocyst.
- the zona pellucida was removed in acid tyrode solution (Sigma, Nicolson JCB 1975) and the blastocysts without zona pellucida prepared in this way were individually incubated for 4 hours in 5 ⁇ l medium containing lentiviral vector. Transduced blastocysts were washed 3 times and then transferred to pseudopregnant ICR female animals. We transplanted 10 blastocysts into each uterine horn. All animal experiments were approved by Osaka University, Institute for Microbial Diseases, and Animal Experimentation Committee.
- Statin pravastatin sodium salt (Cayman Chemical) dissolved in 100% ethanol to make a stock solution (1 mg / ml), diluted in time with sterile PBS (25 ⁇ g / ml), starting from E7.5 unless otherwise indicated And daily intraperitoneal injections up to E18.5 at 5 ⁇ g / animal.
- Atorvastatin (Tronto Research Chemicals Inc) was dissolved in 100% methanol to make a stock solution (25 mg / ml), and diluted with sterile PBS at the time of use (12.5 ⁇ g / ml).
- Each HUVEC cell was diluted to 1 ⁇ M or 10 ⁇ M with a medium and added.
- Blood and urine samples Blood and urine samples Blood samples were coagulated and centrifuged to prepare serum samples. The concentrations of hsFlt1, mVEGF and mPlGF were measured by ELISA kit according to the manufacturer's instructions (R & D system). Aspartate aminotransferase (AST) and alanine transaminase (ALT) were measured by Fuji dry-chem 3500V and dri-chem slides (Fuji Film.co). Urine samples were collected at E18.5. Urine albumin and creatinine concentrations were measured using Fuji dry-chem 3500V and dri-chem slides (Fuji Film.co, Tokyo Japan).
- Blood pressure was measured by the tail cuff method (Softron Ltd, Tokyo, Japan). Mice were lightly fixed without anesthesia in a small cage, and their blood pressure was measured after stabilizing behavior, heart rate, and blood pressure. After stabilization, both systolic pressure and diastolic pressure were recorded at least 5 times until stabilization was disturbed. Average values of both systolic pressure and diastolic pressure measured as described above were used for further statistical analysis.
- Anti-CD31 antibody staining has already been described. Briefly, PFA-fixed samples were rinsed with PBS for 4 hours and continuously immersed in 40%, 70%, 100% methanol at 4 ° C. Sections prepared at 5 ⁇ m thickness were stained with anti-mouse CD31 antibody (BD bioscience) and visualized with Alexa Fluor 488 conjugated goat anti-rat IgG (Molecular Probes). Tissue morphological changes were analyzed using Ehrlich hematoxylin and eosin staining. Samples were visualized using a conventional microscope (DM5500 B; Leica) and images were processed using Adobe Photoshop CS3 software (Adobe Systems).
- HUVEC and HEK293T cells were seeded at 2 ⁇ 10 4 and 1 ⁇ 10 5 cells / well in 6-well plates, respectively, and incubated at 37 ° C. under 5% CO 2 .
- the medium was replaced with fresh medium with or without statins after 24 hours. Further, the medium collected after 24 hours was centrifuged at 1000 ⁇ g, and the supernatant was subjected to ELISA.
- lentiviral vectors were transduced at 100 ng-p24 / ml into blastocysts throughout the experiment.
- PCR and RT-PCR analysis showed that the integration and expression of the LV-hsFLT1 transgene was placenta-specific (FIG. 1b), but placenta-derived hsFLT1 was found in maternal blood. Proven to circulate ( Figures 1c and d).
- the concentration of hsFLT1 in the maternal blood correlated with the amount of lentiviral vector at the time of blastocyst transduction (FIG. 1c).
- circulating hsFLT1 concentration in the mother gradually increased during pregnancy to an average value of 5.84 ⁇ 1.26 ng / ml at 18.5 days of fetal age (E) ( Figure 1d), which is comparable to the sFLT1 concentration (average 4382 pg / ml) in human patients (N Engl J Med. 2004 Feb 12; 350 (7): 672-83., Circulating angiogenic factors and the risk of preeclampsia.).
- pravastatin an HMG-CoA reductase inhibitor
- pravastatin an HMG-CoA reductase inhibitor
- statins are commonly used as drugs for hypercholesterolemia, but recently statins have been reported to have protective effects on vascular endothelial cells (Pharmacol Ther. 2009 Apr; 122 (1) : 30-43. Epub 2009 Jan 23, Statins and cardioprotection--more than just lipid lowering ?, Circulation. 2002 Feb 12; 105 (6): 739-45., Statins have biphasic effects on angiogenesis.).
- administration of pravastatin improved placental dysfunction and prevented miscarriage in spontaneous abortion model mice (Blood.
- hsFLT1 concentration is below the normotensive pregnant woman concentration (average 1642 ng / ml N Engl J Med. 2004 Feb 12; 350 (7): 672-83., Circulating angiogenic factors and the risk of preeclampsia.) there were.
- pravastatin induces PlGF without the influence of LV vector or sFLT1
- statins Teratogenicity is a major concern for pregnant women regarding the clinical application of statins.
- the FDA argues that statins are classified in Category X and that they are not prescribed in the first trimester. However, several recent trials have shown that statins may be safe even in the first trimester (Reprod Toxicol. 2008 Oct; 26 (2): 175-7. Epub 2008 Jul 1., Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes., Br J Clin Pharmacol. 2007 Oct; 64 (4): 496-509. Epub 2007 May 15., Risk anomaly users of statin drugs., Pregnancy outcomes after maternal exposure to simvastatin and lovastatin., Reprod Toxicol.
- statins are very promising for the prevention / amelioration of gestational hypertension syndrome to save many pregnant women and infants around the world from morbidity and death Should be a candidate substance.
- a model animal of pregnancy-induced hypertension syndrome expressing sFLT1 specifically in the placenta and a method for producing the model animal are provided.
- Conventional model animals for gestational hypertension syndrome are produced by overexpression of causative factors in the mother's body, and are incomplete as a disease model.
- hypertensive symptoms appear with the growth of the placenta due to continuation of pregnancy, and the hypertensive symptoms are improved by the dropout of the placenta due to labor.
- the model animal of the present invention has the following advantages compared to the conventional model animal.
- sFLT1 is constitutively expressed throughout pregnancy rather than transiently.
- sFLT1 was introduced into the mother and expressed mainly in the liver, whereas in the method of the present invention, the gene was introduced only into the placenta and expressed without introducing into the mother. For this reason, it has become possible to eliminate the direct influence of virus vector infection on the mother, which could not be done before. In addition, it was possible to eliminate the direct effects of sFLT1 gene expression in the mother.
- statins improve the symptoms of pregnancy-induced hypertension syndrome, placental dysfunction, intrauterine growth retardation, glomerulosclerosis and proteinuria.
- the only treatment for gestational hypertension syndrome is the delivery or placenta removal by caesarean section.
- statin is added as a treatment for pregnancy-induced hypertension syndrome, which is said to be 5-7% of all pregnant women, the economic effect will be great. Furthermore, since the burden of obstetrics due to emergency cesarean section and the burden of neonatal ICU due to early cesarean section can be reduced, the economic effect is great.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
また胚盤胞期胚にレンチウイルスベクターを感染させると、母体や胎児に遺伝子導入されることなく胎盤のみに遺伝子導入できることが証明されている(非特許文献4,5)。
さらに本発明者らは、このモデル動物にプラバスタチン(PS)の投与を試みた。その結果、プラバスタチンがsFLT1に拮抗する胎盤由来増殖因子(PlGF)の発現を誘導して、sFLT1に起因する妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿の症状を改善することを見出した。また本発明者らは、プラバスタチンがPlGFの胎盤以外での異所発現を誘導することを見出した。
本発明はこのような知見に基づくものであり、以下の発明に関する。
〔1〕sFLT1が胎盤特異的に発現していることを特徴とする非ヒト哺乳動物。
〔2〕妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の症状を呈する、〔1〕に記載の非ヒト哺乳動物。
〔3〕以下(a)から(c)を含む工程によって得られる、〔2〕に記載の非ヒト哺乳動物;
(a)非ヒト哺乳動物の胚盤胞の透明帯を除去する工程、
(b)工程(a)で得られた胚盤胞の栄養外胚葉特異的に、sFLT1をコードする核酸を導入する工程、
(c)工程(b)で得られた胚盤胞をレシピエントに移植する工程。
〔4〕以下(a)から(c)の工程を含む、非ヒト哺乳動物の製造方法;
(a)非ヒト哺乳動物の胚盤胞の透明帯を除去する工程、
(b)工程(a)で得られた胚盤胞の栄養外胚葉特異的に、sFLT1をコードする核酸を導入する工程、
(c)工程(b)で得られた胚盤胞をレシピエントに移植する工程。
〔5〕以下(a)から(c)の工程を含む、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿の症状を改善させる物質のスクリーニング方法;
(a)〔1〕から〔3〕のいずれかに記載の非ヒト哺乳動物を取得する工程、
(b)工程(a)で得られた非ヒト哺乳動物に被検物質を投与する工程、及び
(c)被検物質を投与しない場合と比較して、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿の少なくとも1つの症状を改善させる物質を選択する工程。
〔6〕スタチンを有効成分として含有する妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療に用いるための医薬組成物。
〔7〕PlGFまたはPlGFをコードする核酸を有効成分として含有する妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療に用いるための医薬組成物。
〔8〕スタチンを対象に投与する工程を含む、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療方法。
〔9〕PlGFまたはPlGFをコードする核酸を対象に投与する工程を含む、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療方法。
〔10〕妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療に用いるための医薬組成物の製造におけるスタチンの使用。
〔11〕妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療に用いるための医薬組成物の製造におけるPlGFまたはPlGFをコードする核酸の使用。
〔12〕妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療に用いるためのスタチン。
〔13〕妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療に用いるためのPlGFまたはPlGFをコードする核酸。
〔14〕妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療のためのスタチンの使用。
〔15〕妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療のためのPlGFまたはPlGFをコードする核酸の使用。
〔17〕スタチンを有効成分として含有するPlGF誘導促進剤。
〔18〕スタチンを対象に投与する工程を含むPlGFの誘導方法。
〔19〕PlGF誘導剤の製造におけるスタチンの使用。
〔20〕PlGFの誘導に用いるためのスタチン。
〔21〕PlGFの誘導のためのスタチンの使用。
本発明の非ヒト哺乳動物は、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症、タンパク尿などの疾患の症状を示す。また、sFLT1の発現は胎盤特異的であるが、胎盤由来のsFLT1は母体の血液中を循環する。さらに、出産後にこれらの疾患の症状の改善を示すなど、ヒトの病態によく似た経過をたどる。つまり本発明の非ヒト哺乳動物は、好ましい態様において、胎盤を有する間、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症、タンパク尿などの疾患の症状を示す。そして出産に伴い胎盤が体外へ出されると、これらの症状の改善を示す。このような本発明の非ヒト哺乳動物は、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症、タンパク尿などの疾患のモデル動物として有用である。また本発明の非ヒト哺乳動物は、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症、タンパク尿などの疾患の治療や予防のための薬剤の候補化合物のスクリーニング方法に利用することができる。
本発明の好ましい態様において、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症、タンパク尿などの疾患はsFLT1に起因する。
SOSUIを利用して特定されたヒトFLT1の膜貫通ドメインの塩基配列およびアミノ酸配列を配列番号:19および20に示し、マウスFLT1の膜貫通ドメインの塩基配列およびアミノ酸配列を配列番号:21および22に示すが、膜貫通ドメインの配列はこれらに限定されない。
このように当業者であれば、例えばSOSUI(http://bp.nuap.nagoya-u.ac.jp/sosui/)など公知のプログラムを利用して、様々な動物種由来のFLT1における膜貫通ドメインを容易に特定することが出来る。
また当業者であれば、公知の文献をもとに膜貫通ドメインを特定することが可能である。例えば、Flt-1は細胞外に第1から第7の7つの免疫グロブリン様ドメインを有するが、sFlt-1はこれら7つのドメインのうち第1から第6のドメインと、イントロン13の5’領域によってコードされる31アミノ酸を有することが知られている(Shibuya, Cell Structure and Function, 26, 25-35 (2001))。またイントロン13の5’領域によってコードされる31アミノ酸は哺乳動物の間で高度に保存されていることが知られている。さらに、膜貫通ドメインはFLT遺伝子のエクソン16にコードされており、実際にヒトFLT1のエクソン16を欠失させると可溶型になることが知られている(Molecular and Cellular Biology, January 2005, p. 346-354, Vol. 25, No. 1, Membrane Fixation of Vascular Endothelial Growth Factor Receptor 1 Ligand-Binding Domain Is Important for Vasculogenesis and Angiogenesis in Mice)。
当業者であれば、このような情報をもとに、ヒトやマウス、その他の哺乳動物のsFLT1を取得することが可能である。
(1) GenBank: U01134.1より特定される塩基配列(配列番号:1に記載の塩基配列)を有するDNA
(2) NCBI Reference Sequence: NM_002019.4より特定される塩基配列から膜貫通ドメインの塩基配列が除去された塩基配列を有するDNA
またヒトsFLT1タンパク質として以下が挙げられるがこれらに限定されない。
(3) 上記(1)、(2)に記載のDNAによってコードされるアミノ酸配列を有するタンパク質
(4) GenBank: U01134.1やGenBank: AAC50060.1より特定されるアミノ酸配列(配列番号:2に記載のアミノ酸配列)を有するタンパク質
(5) NCBI Reference Sequence: NP_002010.2より特定されるアミノ酸配列から膜貫通ドメインのアミノ酸配列が除去されたアミノ酸配列を有するタンパク質
本発明においてsFLT1をコードする核酸は、「sFLT1をコードするDNA」および「sFLT1をコードするRNA」を含む。
(a)非ヒト哺乳動物の胚盤胞の透明帯を除去する工程、
(b)工程(a)で得られた胚盤胞の栄養外胚葉特異的に、sFLT1をコードする核酸を導入する工程、
(c)工程(b)で得られた胚盤胞をレシピエントに移植する工程。
本発明においてレシピエントは非ヒト哺乳動物であることが好ましい。
このような工程によって得られる非ヒト動物は、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症、タンパク尿などの疾患の症状を示す。
透明帯の除去は上記の方法によって行うことが可能である。しかし本発明における透明帯の除去方法はこれらに限定されず、透明帯を除去することが可能なあらゆる方法が含まれる。
よりストリンジェンシーの高い条件、例えば、6M 尿素、0.4% SDS、0.1×SSCの条件下では、より相同性の高いDNAを単離できると期待される。高い相同性とは、アミノ酸配列全体で少なくとも50%以上、好ましくは70%以上、さらに好ましくは90%以上、最も好ましくは95%以上の配列の同一性を指す。また、変異体における、変異するアミノ酸数は、通常、30アミノ酸以内であり、好ましくは15アミノ酸以内であり、より好ましくは5アミノ酸以内、さらに好ましくは3アミノ酸以内であり、よりさらに好ましくは2アミノ酸以内である。
アミノ酸配列や塩基配列の同一性は、カーリンおよびアルチュールによるアルゴリズムBLAST(Proc. Natl. Acad. Sci. USA 87:2264-2268, 1990、Proc Natl Acad Sci USA 90: 5873, 1993)を用いて判定することができる。
(a)本明細書に記載のsFLT1を胎盤特異的に発現する非ヒト哺乳動物を取得する工程、
(b)工程(a)で得られた非ヒト哺乳動物に被検物質を投与する工程、及び
(c)被検物質を投与しない場合と比較して、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の症状を改善させた物質を選択する工程。
本発明のスクリーニング方法によって得られる物質は、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療剤の候補化合物となり得る。従って妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の症状を改善させる物質のスクリーニング方法は、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療剤の候補化合物のスクリーニング方法と表現することも出来る。
次に、被検物質を本発明のsFLT1を胎盤特異的に発現する非ヒト哺乳動物に投与する。被検物質としては、例えば、天然化合物、有機化合物、無機化合物、タンパク質、ペプチドなどの単一化合物、並びに、化合物ライブラリー、遺伝子ライブラリーの発現産物、細胞抽出物、細胞培養上清、発酵微生物産生物、海洋生物抽出物、植物抽出物等を挙げることができるがこれらに限定されない。
本発明のsFLT1が胎盤特異的に発現する非ヒト哺乳動物への被検化合物の投与は、例えば、経口的または非経口的に行うことができるが、それらに限定されない。被検化合物がタンパク質である場合には、例えば、当該タンパク質をコードする遺伝子を有するウイルスベクターを構築し、その感染力を利用して、本発明の遺伝子改変非ヒト哺乳動物に当該遺伝子を導入することも可能である。
本発明のスクリーニング方法においては、最後に、被検物質が妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の症状を改善させたか否かを判定する。そして、被検物質を投与しない場合と比較して、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の症状を改善させた物質を選択する。例えば、胎盤のPlGFのmRNA量又は母体のPlGFの血液中濃度が増加した場合に、被検物質が妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の症状を改善させたと判定される。PlGFのmRNA量はノザンブロットや定量RT-PCR、マイクロアレイ解析により測定することが出来る。また血液中濃度はウエスタンブロットやELISAにより測定することができる。
あるいは、血圧測定や尿中のアルブミン/クレアチニンを測定し、これらの値が減少した場合、被検物質が妊娠高血圧症候群の症状を改善させたと判定される。さらに腎臓の病理切片の観察により糸球体硬化症を改善させたと判定される場合や、胎盤の病理切片の観察により血管形成不全を改善させたと判定される場合、減少した胎児や胎盤の重量が回復した場合に、症状を改善させたと判定される。
本発明者らは、高脂血症の治療薬として知られるスタチンを本発明者らが開発した非ヒトモデル哺乳動物に投与した結果、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿の症状が改善することを確認した。またスタチン投与によりPlGFの発現が誘導されることを確認した。従って、スタチンやPlGF、PlGFをコードする核酸(DNA、RNA)は妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿の治療薬として有用と考えられる。
・sFLT1の母体血液中濃度を有意に減少させる。
・VEGFの母体血液中濃度に影響を与えない。
・PlGFのmRNA量を有意に誘導する。特に胎盤において約5倍に増加する。
・PlGFの母体血液中濃度を有意に誘導する。
・胎盤形成障害を回復する。
・子宮内胎児発育制限を回復する。
・高血圧を改善する。
・腎機能障害を改善する。
またスタチンは、野生の妊娠雌性動物および非妊娠動物において、循環中のPlGFを有意に増加させる。また正常な妊娠雌性動物において血圧を低下させない。
またプラバスタチンとアトルバスタチンは、ヒト臍帯血内皮細胞(HUVEC)においてPlGFの産生を誘導する。
またPlGFは、sFLT1が胎盤特異的に導入された非ヒト動物において、以下の効果を有する。
・母体血液中のsFLT1を減損させて高血圧症を改善する。
・腎機能障害を改善する。
・胎盤形成障害を回復する。
・子宮内胎児発育制限を回復する。
アトルバスタチン(化学名:(-)-Monocalcium bis{(3R,5R)-7-[2-(4-fluorophenyl-5-isopropyl-3-phenyl-4-phenylcarbamoyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate}trihydrateなど)、
シンバスタチン(化学名:(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl]-ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoateなど)、
セリバスタチン(化学名:(E,3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]-3,5-dihydroxyhept-6-enoic acidなど)
ピタバスタチン(化学名:(+)-monocalcium bis{(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate}など)、
プラバスタチン(化学名:Monosodium(3R,5R)-3,5-dihydroxy-7-{(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyloxy]-1,2,6,7,8,8a-hexahydronaphthalen-l-yl}heptanoate)、
フルバスタチン(化学名(±)-(3RS ,5SR ,6E )-Sodium-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H -indol-2-yl]-3,5-dihydroxy-6-heptenoateなど)、
ロスバスタチン(化学名:Monocalcium bis((3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methanesulfonyl(methyl)amino] pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoate) など)、
ロバスタチン(化学名:[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate)など)
などが知られている。
メバスタチン以外のスタチンは、当業者であれば特表2009-538831の記載に従い合成することが可能である。またメバスタチンについては、当業者であれば、例えばJournal of Lipid Research Volume 33, 1992に記載の方法により入手することが可能である。あるいは、プラバスタチンはCayman chemical、アトロバスタチンはTronto Research Chemicalsから購入することも可能である。さらに、処方薬として多くの製薬会社より入手することが可能である。
PlGF遺伝子及び当該遺伝子によりコードされる蛋白質はチンパンジー、ラット、犬、牛、馬、豚、羊などにおいても知られている。各々のアクセッション番号を以下に示す。
NCBI Reference Sequence
チンパンジー :遺伝子XM_001158223.1 タンパク質XP_001158223.1
ラット :遺伝子NM_053595.2 タンパク質NP_446047.1
犬 :遺伝子XM_849639.1 タンパク質XP_854732.1
牛 :遺伝子NM_173950.2 タンパク質NP_776375.1
馬 :遺伝子XM_001491442.1 タンパク質XP_001491492.1
Gnenbank
豚 :遺伝子FJ177137.1 タンパク質ACI24003.1
羊 :遺伝子AY157708.1 タンパク質AAN77495.1
本発明の薬剤における「PlGFをコードする核酸」としては、「PlGFをコードするDNA」および「PlGFをコードするRNA」を挙げることが出来る。「PlGFをコードするDNA」の形態としては、特に制限はなく、ゲノムDNA、cDNA、合成DNA、またはそれらのDNAを含むベクターであってもよい。
また、PlGFをグルタチオン S-トランスフェラーゼ蛋白質との融合ポリペプチドとして、あるいはヒスチジンを複数付加させた組み換えポリペプチドとして宿主細胞(例えば、動物細胞や大腸菌など)内で発現させた場合には、発現させた組み換えポリペプチドはグルタチオンカラムあるいはニッケルカラムを用いて精製することができる。
また、ベクターには、ポリペプチド分泌のためのシグナル配列が含まれていてもよい。ポリペプチド分泌のためのシグナル配列としては、大腸菌のペリプラズムに産生させる場合、pelBシグナル配列(Lei, S. P. et al J. Bacteriol. (1987) 169, 4379)を使用すればよい。宿主細胞へのベクターの導入は、例えば塩化カルシウム法、エレクトロポレーション法を用いて行うことができる。
また、in vivoでポリペプチドを産生させる系としては、例えば、動物を使用する産生系や植物を使用する産生系が挙げられる。この動物または植物にPlGFをコードする核酸を導入し、動物または植物の体内でPlGFを産生させ、回収する。
動物を使用する場合、哺乳類動物、昆虫を用いる産生系がある。哺乳類動物としては、ヤギ、ブタ、ヒツジ、マウス、ウシを用いることができる(Vicki Glaser, SPECTRUM Biotechnology Applications, 1993)。また、哺乳類動物を用いる場合、トランスジェニック動物を用いることができる。
例えば、PlGFをコードする核酸を、ヤギβカゼインのような乳汁中に固有に産生されるポリペプチドをコードする遺伝子との融合遺伝子として調製する。次いで、この融合遺伝子を含むDNA断片をヤギの胚へ注入し、この胚を雌のヤギへ移植する。胚を受容したヤギから生まれるトランスジェニックヤギ又はその子孫が産生する乳汁から、PlGFを得ることができる。トランスジェニックヤギから産生されるポリペプチドを含む乳汁量を増加させるために、適宜ホルモンをトランスジェニックヤギに使用してもよい(Ebert, K.M. et al., Bio/Technology (1994) 12, 699-702)。
なお、本発明のPlGFを精製前又は精製後に適当な蛋白質修飾酵素を作用させることにより、任意に修飾を加えたり部分的にペプチドを除去することもできる。蛋白質修飾酵素としては、例えば、トリプシン、キモトリプシン、リシルエンドペプチダーゼ、プロテインキナーゼ、グルコシダーゼ等が用いられる。
上記治療剤は、経口、非経口投与のいずれでも可能であるが、好ましくは非経口投与であり、具体的には、注射剤型、経鼻投与剤型、経肺投与剤型、経皮投与型などが挙げられる。注射剤型の例としては、例えば、静脈内注射、筋肉内注射、腹腔内注射、皮下注射などにより全身または局部的に投与することができる。
PlGFをコードする核酸を生体内に投与する場合には、レトロウイルス、アデノウイルス、センダイウイルスなどのウイルスベクターやリポソームなどの非ウイルスベクターを利用することができる。投与方法としては、in vivo法およびex vivo法を例示することができる。
油性液としてはゴマ油、大豆油があげられ、溶解補助剤として安息香酸ベンジル、ベンジルアルコールと併用してもよい。また、緩衝剤、例えばリン酸塩緩衝液、酢酸ナトリウム緩衝液、無痛化剤、例えば、塩酸プロカイン、安定剤、例えばベンジルアルコール、フェノール、酸化防止剤と配合してもよい。調製された注射液は通常、適当なアンプルに充填させる。
なお本発明の治療剤、特にプラバスタチンは、高血圧症の初期より毎日投与することが好ましい。より具体的には、例えばヒトの場合、妊娠20週よりあるいはそれよりも前より、毎日投与することが好ましい。また例えばマウスの場合、好ましくは13日目より、より好ましくは10日目より、さらに好ましくは7日目より毎日投与することが好ましい。
また本発明の治療剤は、高血圧発症前から毎日投与することがさらに好ましい。
なお本明細書において引用された全ての先行技術文献は、参照として本明細書に組み入れられる。
1.方法
プライマーおよびPCR
ヒトsFLT1 (hsFLT1) cDNAを、プライマー5’-aaggatccgccgccatggtcagctactgggac-3’(配列番号:7)および5’-ttctcgagttaatgttttacattactttgtgtg-3’(配列番号:8)によってHUVEC(Kurabo)からRT-PCRによって増幅した。マウスPlGF (mPlGF) cDNAを、プライマー5’-aagaattcgccaccatgctggtcatgaagctgttc-3’(配列番号:9)および5’-ttctcgagtcacgggtggggttcctcag-3’(配列番号:10)によってE13.5胎盤からRT-PCRによって増幅した。図1bにおいて、プライマー5'-aagtgtgacgttgacatccg-3'(配列番号:11)および5'-gatccacatctgctggaagg-3'(配列番号:12)をmActbの増幅に、5'-ggctgagcataactaaatctgcc-3'(配列番号:13)および 5'-ggaatgacgagctcccttccttca-3'(配列番号:14)を hsFLT1の増幅に用いた。図2cにおいて、プライマー5'-catccgtaaagacctctatgccaac-3'(配列番号:15)および5'-atggagccaccgatccaca-3'(配列番号:16)をmActbの増幅に、5'-tgctgggaacaactcaacag-3'(配列番号:17)および 5'-cctcatcagggtattcatcca-3'(配列番号:18)をmPlGFの増幅に用いた。
HIV-Iに基づく自己不活化レンチウイルスベクタープラスミドpLV-EGFPは既に記述された(Nat Biotechnol. 2007 Feb;25(2):233-7.)。他のレンチウイルスベクタープラスミドpLV-hsFLT1およびpLV-mPlGFは、EGFP cDNAをhsFLT1およびmPlGF cDNAにそれぞれ交換することによって調製した。水疱性口内炎ウイルス糖タンパク質シュードタイプレンチウイルスベクターを生成して、p24 gag抗原濃度を既に記述されているように測定した(Nat Genet. 2000 Jun;25(2):217-22.)。
野生型B6D2F1雌性動物を、妊娠雌馬の血清ゴナドトロピン(5単位)の腹腔内注射の48時間後にヒト絨毛ゴナドトロピン(5単位)によって過剰排卵させた後、野生型B6D2 F1雄性動物と交配させた。交尾後1.5日目の雌性動物から2細胞から4細胞期胚を採取して、kSOM培地(erbach BOR 1994)において2日間インキュベートして、胚盤胞を得た。酸性タイロード液(Sigma, Nicolson JCB 1975)において透明帯を除去して、このように調製した透明帯を含まない胚盤胞を、レンチウイルスベクターを含有する培地5μlにおいて個々に4時間インキュベートした。形質導入された胚盤胞を3回洗浄した後、偽妊娠ICR雌性動物に移植した。本発明者らは、それぞれの子宮角に胚盤胞10個を移植した。動物実験は全て、大阪大学・微生物病研究所・動物実験委員会によって承認された。
プラバスタチンナトリウム塩(Cayman Chemical)を100%エタノールに溶解してストック溶液とし(1mg/ml)、滅菌PBSによって用時希釈、(25μg/ml)、特に指示していなければE7.5から開始して、5μg/匹でE18.5まで毎日腹腔内注射した。
アトルバスタチン(Tronto Research Chemicals Inc)を100%メタノールに溶解してストック溶液とし(25mg/ml)、滅菌PBSにて用時希釈した(12.5μg/ml)。
HUVEC細胞には、それぞれを培地にて1μMもしくは10μMに希釈して添加した。
血液試料を凝固させて遠心して血清試料を調製した。hsFlt1、mVEGFおよびmPlGFの濃度をELISAキットによって製造元の説明書(R&D system)に従って測定した。アスパラギン酸アミノトランスフェラーゼ(AST)およびアラニントランスアミナーゼ(ALT)を、Fuji dry-chem 3500V and dri-chemスライド(Fuji Film.co)によって測定した。尿試料をE18.5に採取した。尿アルブミンおよびクレアチニン濃度を、Fuji dry-chem 3500V and dri-chemスライド(Fuji Film.co, Tokyo Japan)を用いて測定した。
血圧は、テールカフ法(Softron Ltd,Tokyo,Japan)によって測定した。マウスを小さいケージにおいて麻酔せずに軽く固定して、行動、心拍数、および血圧を安定化させた後にその血圧を測定した。安定化後、収縮期圧および拡張気圧の双方を、安定化が乱れるまで少なくとも5回記録した。上記のように測定した収縮期圧および拡張気圧の双方の平均値を、さらなる統計分析のために用いた。
屠殺したマウスから採取した胎盤を4%パラホルムアルデヒド(PFA)/PBSにおいて12時間固定した後、さらなる染色に供した。抗CD31抗体染色は既に記述された。簡単に説明すると、PFA固定試料をPBSによって4時間すすぎ、4℃で40%、70%、100%メタノールに連続的に浸した。厚さ5μmで調製した切片を抗マウスCD31抗体(BD bioscience)によって染色して、Alexa Fluor 488共役ヤギ抗ラットIgG(Molecular Probes)によって可視化した。組織の形態学的変更を、Ehrlichヘマトキシリン・エオジン染色を用いて分析した。試料を従来の顕微鏡(DM5500 B;Leica)を用いて可視化して、画像をAdobe Photoshop CS3ソフトウェア(Adobe Systems)を用いて処理した。
HUVECおよびHEK293T細胞をそれぞれ、6ウェルプレートにおいて2×104個および1×105個/ウェルで播種して、5%CO2下で37℃でインキュベートした。培地を、24時間後にスタチンを含むまたは含まない新しい培地に交換した。さらに24時間後に採取した培地を1000×gで遠心して、上清をELISAに供した。
値は全て、平均値±s.e.m.として表記する。本発明者らは、両側の対応のないStudent’s t-検定によって群の間で比較した。本発明者らはP値<0.05を有意とみなした。
妊娠高血圧症候群の新規動物モデルを開発するために、本発明者らは、妊娠期間を通してマウス胎盤においてhsFLT1を特異的に発現させた(図1)。本発明者らは以前に、胚盤胞の栄養外胚葉細胞にレンチウイルス(LV)ベクターを形質導入すると、胎盤特異的遺伝子組み込みおよび発現が起こることを示している(Nat Biotechnol. 2007 Feb;25(2):233-7.)。この方法に従って、本発明者らは、透明帯を含まない胚盤胞にhsFLT1を発現するLVベクター(LV-hsFLT1)を形質導入して、それらを偽妊娠雌性動物に移植した(図1a)。特に指示されていなければ、実験を通して胚盤胞にレンチウイルスベクターを100 ng-p24/mlで形質導入した。本発明者らが予想したように、PCRおよびRT-PCR分析により、LV-hsFLT1トランスジーンの組み込みおよび発現は胎盤特異的であったが(図1b)、胎盤由来hsFLT1は、母体の血液中を循環することが証明された(図1cおよびd)。
具体的には、本発明のモデル動物は従来のモデル動物と比較し、次のような利点を有する。
(1)好ましい態様においてレンチウイルスベクターを使用することで、一過性ではなく妊娠期間を通じて恒常的にsFLT1発現する。
(2)従来はsFLT1を母体に遺伝子導入して主に肝臓で発現させていたのに対し、本発明の方法では、母体に遺伝子導入することなく胎盤のみに遺伝子導入して発現させている。そのため従来はできなかった、ウイルスベクター感染が母体に及ぼす直接的な影響を排除することが可能となった。また、母体でsFLT1遺伝子が発現することによる直接的な影響を排除することが可能となった。
(3)従来法ではsFLT1が母体全体に発現するので出産に関係なく病態が維持されるのに対し、本発明の方法では胎盤特異的に発現させるので出産後は病態が改善する。ヒトでも同じ経過をたどることから、患者病態をより反映したモデルと言える。
更に本発明において、スタチンによって妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿の症状が改善されることが明らかとなった。現時点で、妊娠高血圧症候群の治療法としては、分娩もしくは帝王切開による胎盤除去しか存在しない。全妊婦の5-7%と言われる妊娠高血圧症候群の治療薬としてスタチンが効能追加されれば、経済効果が大きい。さらに緊急帝王切開による産科の負担や、早期帝王切開による新生児ICUなどの負担も軽減できることから、経済的効果も大きい。
Claims (8)
- sFLT1が胎盤特異的に発現していることを特徴とする非ヒト哺乳動物。
- 妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の症状を呈する、請求項1に記載の非ヒト哺乳動物。
- 以下(a)から(c)を含む工程によって得られる、請求項2に記載の非ヒト哺乳動物;
(a)非ヒト哺乳動物の胚盤胞の透明帯を除去する工程、
(b)工程(a)で得られた胚盤胞の栄養外胚葉特異的に、sFLT1をコードする核酸を導入する工程、
(c)工程(b)で得られた胚盤胞をレシピエントに移植する工程。 - 以下(a)から(c)の工程を含む、非ヒト哺乳動物の製造方法;
(a)非ヒト哺乳動物の胚盤胞の透明帯を除去する工程、
(b)工程(a)で得られた胚盤胞の栄養外胚葉特異的に、sFLT1をコードする核酸を導入する工程、
(c)工程(b)で得られた胚盤胞をレシピエントに移植する工程。 - 以下(a)から(c)の工程を含む、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患を改善させる物質のスクリーニング方法;
(a)請求項1から3のいずれかに記載の非ヒト哺乳動物を取得する工程、
(b)工程(a)で得られた非ヒト哺乳動物に被検物質を投与する工程、及び
(c)被検物質を投与しない場合と比較して、妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の症状を改善させる物質を選択する工程。 - スタチンを有効成分として含有する妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療に用いるための医薬組成物。
- PlGFまたはPlGFをコードする核酸を有効成分として含有する妊娠高血圧症候群、胎盤機能不全、子宮内胎児発育遅延、糸球体硬化症およびタンパク尿からなる群より選択される少なくとも1つの疾患の治療に用いるための医薬組成物。
- スタチンを有効成分として含有するPlGF誘導促進剤。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11750820.0A EP2543729B1 (en) | 2010-03-04 | 2011-03-04 | Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor |
US13/581,510 US9029627B2 (en) | 2010-03-04 | 2011-03-04 | Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor |
JP2012503291A JP5885657B2 (ja) | 2010-03-04 | 2011-03-04 | 妊娠高血圧症候群モデル動物とその治療方法 |
US14/686,166 US9700024B2 (en) | 2010-03-04 | 2015-04-14 | Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-048237 | 2010-03-04 | ||
JP2010048237 | 2010-03-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/581,510 A-371-Of-International US9029627B2 (en) | 2010-03-04 | 2011-03-04 | Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor |
US14/686,166 Continuation US9700024B2 (en) | 2010-03-04 | 2015-04-14 | Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011108711A1 true WO2011108711A1 (ja) | 2011-09-09 |
Family
ID=44542355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/055087 WO2011108711A1 (ja) | 2010-03-04 | 2011-03-04 | 妊娠高血圧症候群モデル動物とその治療方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US9029627B2 (ja) |
EP (1) | EP2543729B1 (ja) |
JP (1) | JP5885657B2 (ja) |
WO (1) | WO2011108711A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815598B2 (en) | 2005-08-12 | 2014-08-26 | Masaru Okabe | Trophectodermal cell-specific gene transfer methods |
JP2015030721A (ja) * | 2013-08-07 | 2015-02-16 | 国立大学法人東北大学 | ニコチンアミドによる妊娠高血圧症候群、流産・早産、及び子宮内胎児発育遅延の改善 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110123478A (zh) * | 2019-06-12 | 2019-08-16 | 西南医科大学附属医院 | 一种带有锚定线结的血管套管及使用方法 |
KR102253790B1 (ko) * | 2019-11-19 | 2021-05-21 | 고려대학교 산학협력단 | 임신성 고혈압 동물모델 및 이의 제조방법 |
RU2763837C1 (ru) * | 2021-07-08 | 2022-01-11 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени. Д.О. Отта" | Способ моделирования иммунопатологической плацентарной недостаточности |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007020786A1 (ja) * | 2005-08-12 | 2007-02-22 | Fuso Pharmaceutical Industries, Ltd. | 栄養外胚葉細胞特異的遺伝子導入法 |
JP2007518769A (ja) * | 2004-01-23 | 2007-07-12 | イーピーオープラス ゲーエムベーハー ウント コムパニー カーゲー | 内皮前駆細胞の刺激並びに臓器の再生及び内臓障害の進行の抑制のための低用量エリスロポエチンの使用 |
JP2009538831A (ja) | 2007-04-18 | 2009-11-12 | テバ ファーマシューティカル インダストリーズ リミティド | ロスバスタチン中間体及びロスバスタチンの調製方法。 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000026438A (ja) * | 1998-07-14 | 2000-01-25 | Fujimoto Brothers:Kk | 新規な2−(n−シアノイミノ)チアゾリジン−4− オン誘導体 |
CA2922031C (en) | 2002-07-19 | 2020-12-15 | Beth Israel Deaconess Medical Center, Inc. | Methods of diagnosing and treating pre-eclampsia or eclampsia |
JP2008026438A (ja) | 2006-07-19 | 2008-02-07 | Sumitomo Chemical Co Ltd | 複合偏光板、その製造法、複合光学部材及び液晶表示装置 |
-
2011
- 2011-03-04 EP EP11750820.0A patent/EP2543729B1/en active Active
- 2011-03-04 US US13/581,510 patent/US9029627B2/en active Active
- 2011-03-04 JP JP2012503291A patent/JP5885657B2/ja active Active
- 2011-03-04 WO PCT/JP2011/055087 patent/WO2011108711A1/ja active Application Filing
-
2015
- 2015-04-14 US US14/686,166 patent/US9700024B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007518769A (ja) * | 2004-01-23 | 2007-07-12 | イーピーオープラス ゲーエムベーハー ウント コムパニー カーゲー | 内皮前駆細胞の刺激並びに臓器の再生及び内臓障害の進行の抑制のための低用量エリスロポエチンの使用 |
WO2007020786A1 (ja) * | 2005-08-12 | 2007-02-22 | Fuso Pharmaceutical Industries, Ltd. | 栄養外胚葉細胞特異的遺伝子導入法 |
JP2009538831A (ja) | 2007-04-18 | 2009-11-12 | テバ ファーマシューティカル インダストリーズ リミティド | ロスバスタチン中間体及びロスバスタチンの調製方法。 |
Non-Patent Citations (53)
Title |
---|
"Manipulating the mouse embryo, a laboratory manual", COLD SPRING HARBOR LABORATORY PRESS, pages: 201 - 203 |
"Manipulating the mouse embryo, a laboratory manual", COLD SPRING HARBOR LABORATORY PRESS, pages: 263 - 271 |
"Manipulating the mouse embryo, a laboratory manual", COLD SPRING HARBOR LABORATORY PRESS, pages: 485 - 486 |
"Manipulating the mouse embryo, a laboratory manual", COLD SPRING HARBOR LABORATORY PRESS, pages: 731 |
"Membrane Fixation of Vascular Endothelial Growth Factor Receptor 1 Ligand-Binding Domain Is Important for Vasculogenesis and Angiogenesis in Mice", MOLECULAR AND CELLULAR BIOLOGY, vol. 25, no. 1, January 2005 (2005-01-01), pages 346 - 354 |
AM J PHYSIOL HEART CIRC PHYSIOL., vol. 294, no. 3, 11 January 2008 (2008-01-11), pages 3 81 - 7 |
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043 |
BLOOD., vol. 113, no. 17, 20 February 2009 (2009-02-20), pages 4101 - 9 |
BR J CLIN PHARMACOL., vol. 64, no. 4, 15 May 2007 (2007-05-15), pages 496 - 509 |
CIRCULATION, vol. 105, no. 6, 12 February 2002 (2002-02-12), pages 739 - 45 |
DEVELOPMENTAL BIOLOGY, vol. 250, 2002, pages 348 - 357 |
EBERT, K. M., BIO/TECHNOLOGY, vol. 12, 1994, pages 699 - 702 |
FASEB J., vol. 6, 1992, pages 2422 - 2427 |
GENESIS, vol. 47, no. 12, December 2009 (2009-12-01), pages 793 - 8 |
HAFEZ: "Theriogenology", 1992, SHOTEN, article "Bovine Embryo Transplantation" |
HIROMASA SUZUKI ET AL.: "sFlt-1 Kajo Hatsugen ni yoru Ninshin Koketsuatsu Jinsho-yo Mouse Model ni Okeru, Kekkan Shinsei Inshi Toyo ni yoru Kecchu NO eno Eikyo", ACTA OBSTETRICA ET GYNAECOLOGIA JAPONICA, vol. 62, no. 2, February 2010 (2010-02-01), pages 492 * |
HIROSHI KOBAYASHI: "Byotaibetsu ni Mita DIC no Shindan to Chiryo 6 Sanfujinka Ryoiki", BIOMEDICINE & THERAPEUTICS, vol. 41, no. 3, 2007, pages 265 - 268 * |
HUM. REPROD., vol. 15, 2000, pages 1061 - 1064 |
HUM. REPROD., vol. 5, 1990, pages 7 - 13 |
HYPERTENSION, vol. 54, no. 5, 28 September 2009 (2009-09-28), pages 1129 - 35 |
HYPERTENSION., vol. 50, no. 4, 27 August 2007 (2007-08-27), pages 686 - 92 |
J CLIN INVEST., vol. 111, no. 5, March 2003 (2003-03-01), pages 649 - 58 |
JOURNAL OF LIPID RESEARCH, vol. 33, 1992 |
JULIAN K.-C. MA ET AL., EUR. J. IMMUNOL., vol. 24, 1994, pages 131 - 138 |
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268 |
KODAMA, Y. ET AL.: "Atorvastatin Increases Plasma sFlt-1 and Decreases VEGF and P1GF in Association with Improvement of Ventricular Function in Acute Myocardial Infarction", CIRC J, vol. 71, no. SUPL.1, 2007, pages 670 * |
KODAMA, Y. ET AL.: "Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 48, no. 1, 2006, pages 43 - 50, XP028006623 * |
KUMASAWA, K. ET AL.: "Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model", PROC NATL ACAD SCI USA, vol. 108, no. 4, 25 January 2011 (2011-01-25), pages 1451 - 1455, XP002701225 * |
LANCET, vol. 367, no. 9516, 1 April 2006 (2006-04-01), pages 1066 - 74 |
LANCET., vol. 367, no. 9516, 1 April 2006 (2006-04-01), pages 1066 - 74 |
LEI, S. P. ET AL., J. BACTERIOL., vol. 169, 1987, pages 4379 |
LOBODA, A. ET AL.: "Angiogenic transcriptome of human microvascular endothelial cells: Effect of hypoxia, modulation by atorvastatin", VASCULAR PHARMACOLOGY, vol. 44, no. 4, 2006, pages 206 - 214, XP024969976 * |
MAYNARD SE ET AL.: "Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia", J CLIN INVEST., vol. 111, no. 5, March 2003 (2003-03-01), pages 649 - 658, XP002570650 * |
MIZUSHIMA ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322 |
MOLECULAR THERAPY, vol. 8, 2003, pages 666 - 673 |
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108 |
N ENGL J MED., vol. 350, no. 7, 12 February 2004 (2004-02-12), pages 672 - 83 |
N ENGL J MED., vol. 350, no. 7, 5 February 2004 (2004-02-05), pages 672 - 83 |
NAT BIOTECHNOL., vol. 25, no. 2, February 2007 (2007-02-01), pages 233 - 7 |
NAT GENET., vol. 25, no. 2, June 2000 (2000-06-01), pages 217 - 22 |
NAT. BIOTECHNOL., vol. 25, no. 2, February 2007 (2007-02-01), pages 233 - 7 |
NUCLEIC ACIDS RES., vol. 18, no. 17, 1990, pages 5322 |
PHARMACOL THER., vol. 122, no. 1, 23 January 2009 (2009-01-23), pages 30 - 43 |
PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 |
REPROD TOXICOL., vol. 10, no. 6, November 1996 (1996-11-01), pages 439 - 46 |
REPROD TOXICOL., vol. 26, no. 2, 1 July 2008 (2008-07-01), pages 175 - 7 |
SAIKI, R. K. ET AL., SCIENCE, vol. 230, 1985, pages 1350 - 1354 |
SAIKI, R. K. ET AL., SCIENCE, vol. 239, 1988, pages 487 - 491 |
See also references of EP2543729A4 |
SHIBUYA, CELL STRUCTURE AND FUNCTION, vol. 26, 2001, pages 25 - 35 |
SOUTHERN, E. M., JOURNAL OF MOLECULAR BIOLOGY, vol. 98, 1975, pages 503 |
SUSUMU, M. ET AL., NATURE, vol. 315, 1985, pages 592 - 594 |
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815598B2 (en) | 2005-08-12 | 2014-08-26 | Masaru Okabe | Trophectodermal cell-specific gene transfer methods |
JP2015030721A (ja) * | 2013-08-07 | 2015-02-16 | 国立大学法人東北大学 | ニコチンアミドによる妊娠高血圧症候群、流産・早産、及び子宮内胎児発育遅延の改善 |
Also Published As
Publication number | Publication date |
---|---|
JP5885657B2 (ja) | 2016-03-15 |
EP2543729A4 (en) | 2013-08-21 |
US20130198874A1 (en) | 2013-08-01 |
EP2543729B1 (en) | 2017-11-01 |
US20150264901A1 (en) | 2015-09-24 |
JPWO2011108711A1 (ja) | 2013-06-27 |
US9029627B2 (en) | 2015-05-12 |
EP2543729A1 (en) | 2013-01-09 |
US9700024B2 (en) | 2017-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Davenport et al. | Autism and schizophrenia-associated CYFIP1 regulates the balance of synaptic excitation and inhibition | |
US11253571B2 (en) | Preventive or therapeutic agent for kidney disease | |
US9700024B2 (en) | Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor | |
Planès et al. | ENaC‐mediated alveolar fluid clearance and lung fluid balance depend on the channel‐activating protease 1 | |
JP2013121357A (ja) | タンパク質、それをコードする核酸および関連する使用方法 | |
JP6212659B2 (ja) | ヒト化ジペプチジルペプチダーゼiv(dpp4)動物 | |
Mishra et al. | Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration | |
Gong et al. | Aberrant expression of imprinted genes and their regulatory network in cloned cattle | |
WO2006028241A1 (ja) | 動脈硬化の予防・治療用医薬 | |
Liu et al. | POLR2A blocks osteoclastic bone resorption and protects against osteoporosis by interacting with CREB1 | |
Fujioka et al. | Targeting retrovirus-derived Rtl8a and 8b causes late onset obesity and neurodevelopmental defects | |
TW202307213A (zh) | 血管收縮素轉化酶ii(ace2)基因轉殖動物及其用途 | |
Bi et al. | ERp44 is required for endocardial cushion development by regulating VEGFA secretion in myocardium | |
US8603992B2 (en) | Compositions comprising MG29 nucleic acids, polypeptides, and associated methods of use | |
US20100329987A1 (en) | Uses of Sperm Membrane Protein OBF | |
Moreno et al. | Restricted transgene persistence after lentiviral vector‐mediated fetal gene transfer in the pregnant rabbit model | |
Coppola | The role of Furin in type 2 diabetes and obesity | |
JP6587091B2 (ja) | 寿命短縮化モデル非ヒト哺乳動物 | |
Liu et al. | A tissue injury repair pathway distinct but parallel to host pathogen defense | |
Dietsche | The effect of Knockout and Mutation of the Transmembrane BAX Inhibitor Motif containing protein 5 (TMBIM5) on cellular and mitochondrial function in cells and mice | |
Mishra et al. | Integrative Cardiovascular Physiology and Pathophysiology: Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration | |
Takashima et al. | Null mutation of exocyst complex component 3-like does not affect vascular development in mice | |
JP2023534035A (ja) | SARS-CoV-2感染のためのヒト化マウスモデル | |
Farah | Porcupine-dependant Wnt signaling is required for proper uterine development and function | |
WO2004078208A1 (ja) | MIP-3α抑制薬の医薬用途および脳・神経細胞保護剤のスクリーニング方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11750820 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012503291 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011750820 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011750820 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13581510 Country of ref document: US |